The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis

Rejeski K, Perez A, Sesques P, Berger C, Jentzsch L, Mougiakakos D, Froelich L, Ackermann J, Buecklein , Blumenberg , Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Hoster E, Locke F, Von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain M, Subklewe M (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 257-257

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Dimitrios Mougiakakos Medizinische Fakultät Andreas Mackensen Lehrstuhl für Innere Medizin V

Involved external institutions

Memorial Sloan Kettering Cancer Center US United States (USA) (US) Universitätsklinikum Tübingen DE Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) DE Germany (DE) Hospices Civils de Lyon (CHU) FR France (FR) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) H. Lee Moffitt Cancer Center & Research Institute US United States (USA) (US)

How to cite

APA:

Rejeski, K., Perez, A., Sesques, P., Berger, C., Jentzsch, L., Mougiakakos, D.,... Subklewe, M. (2021). The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis. In ONCOLOGY RESEARCH AND TREATMENT (pp. 257-257). BASEL: KARGER.

MLA:

Rejeski, K., et al. "The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2021. 257-257.

BibTeX: Download